The article is frequently cited in discussions about the limitations of current ADHD drug therapies, which often lack long-term safety evidence and may be less preferred by parents and clinicians than non-pharmacological alternatives.
The review synthesizes three decades of research, specifically focusing on the transition from identifying brain differences in ADHD through MRI to targeting those deficits with modern neurotherapeutics. Rubia (2022)
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more Neurotherapeutics for ADHD: Do they work? - Rubia - 2022 The article is frequently cited in discussions about
: Rubia suggests that "one-size-fits-all" approaches are likely to fail. Future success depends on personalizing treatment based on a patient’s neurocognitive or brain-imaging patterns. Clinical Context For medical advice or diagnosis, consult a professional
Most studies have been small with heterogeneous designs, often testing effects on cognitive functions rather than clinical symptoms.
: Using EEG (most common), functional near-infrared spectroscopy (fNIRS), and functional MRI (fMRI).